SAI Life Sciences Ltd. · NSE:SAILIFE

SAI Life Sciences — Q2 FY2027 Earnings Presentation

34 slides from SAI Life Sciences's earnings presentation, Nov 6, 2026

  1. Slide 1: Regulation 30 Filing Cover Letter to NSE and BSE

    06th November 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: SAILIFE BSE Scrip code: 544306 Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“SEBI Li

  2. Slide 2: Sai Life Sciences Investor Presentation

    Sai Life Sciences Investor Presentation November 05, 2026 1 All rights reserved © 2026 Sai Life Sciences Limited

  3. Slide 3: Safe Harbour

    Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "

  4. Slide 4: CEO Message: Q2 FY27 was a strong quarter

    “ Q2 FY27 was a strong quarter for Sai, with continued business momentum and progress across our key strategic priorities. We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabi

  5. Slide 5: CFO Message: Healthy performance this quarter

    “ We are pleased to report a healthy performance this quarter, with revenue growing by 23% year- on-year. The performance was broad-based, with both CRO and CDMO delivering healthy growth, while EBITDA margins stood at 28%. We continue to expect a stronger second half, supported by the progression o

  6. Slide 6: Executive Summary

    Executive Summary 5 All rights reserved © 2026 Sai Life Sciences Limited 5 All rights reserved © 2026 Sai Life Sciences Limited

  7. Slide 7: H1 FY27 Half-yearly Snapshot

    H1 FY27 Half-yearly Snapshot ₹ 1,213 Cr ₹ 893 Cr ₹ 335 Cr ₹ 172 Cr Revenue Material Margin EBITDA PAT 17% YoY 19% YoY 19% YoY 19% YoY 62 % 38 % ₹ 621 Cr CDMO Revenue Mix CRO Revenue Mix Capex Incurred 6 All rights reserved © 2026 Sai Life Sciences Limited

  8. Slide 8: Q2 FY27 Quarterly Snapshot

    Q2 FY27 Quarterly Snapshot ₹ 659 Cr ₹ 484 Cr ₹ 187 Cr ₹ 98 Cr Revenue Material Margin EBITDA PAT 23% YoY 22% YoY 20% YoY 17% YoY 64 % 36% ₹ 358 Cr 67 % CDMO Revenue Mix CRO Revenue Mix Capex Incurred Capacity Utilization 7 All rights reserved © 2026 Sai Life Sciences Limited

  9. Slide 9: Consolidated Financial Highlights (Half Yearly)

    Consolidated Financial Highlights (Half Yearly) Revenue (₹Cr) Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 73% 74% 28% 1,213 27% 14% 14% 893 1,034 753 335 281 172 144 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 17% 19% 19% 19% YoY Growth YoY Growth

  10. Slide 10: Consolidated Financial Highlights (Quarterly)

    Consolidated Financial Highlights (Quarterly) Revenue (₹Cr) Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 659 74% 73% 29% 16% 15% 28% 484 537 397 187 156 84 98 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 23% 22% 20% 17% YoY Growth YoY Growth YoY Gro

  11. Slide 11: Business Updates

    Business Updates Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3 10 All rights reserved © 2026 Sai Life Sciences Limited

  12. Slide 12: Business Updates

    Business Updates • Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3 • Converted another large pharma relationship into a similar strategic engagement • Working on expanding the integrated outsourcing mod

  13. Slide 13: Company Overview

    Company Overview 12 All rights reserved © 2026 Sai Life Sciences Limited 12 All rights reserved © 2026 Sai Life Sciences Limited

  14. Slide 14: Sai Life Sciences: At a Glance

    Sai Life Sciences: At a Glance Integrated CRDMO Outsourcing Offer complete Contract Research, partner to services from Development and pharma drug discovery to Manufacturing innovators manufacturing Organization 27 Years Global Partner Expansive Innovation-Led of Expertise of Choice Infrastructure G

  15. Slide 15: Key Highlights

    Key Highlights Fastest growing NSE/BSE 4,400+ 300+ Indian CRDMO Listed on the Indian Total employees* Active customers across Stock Exchanges in US, UK, EU, Japan over the last 5 years Dec 2024 11+ years 19/25 USFDA, PMDA Diverse Enduring customer of the largest pharmaceutical relationships companie

  16. Slide 16: Growth journey

    Growth journey 1999 – 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & CDMO pivot Biology foray; CDMO Globalization, Increasing capacity early biotech foray Consolidation scaled-up & strengthening integrated CRDMO new-age modalities • Incorporated in 1999; • First USFDA approval •

  17. Slide 17: Global Presence

    Global Presence Research laboratories for discovery and development located near overseas innovation hubs in Greater Global Team Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. 4,400+ Bidar, India E

  18. Slide 18: Integrated CRDMO delivering value across the value chain

    Integrated CRDMO delivering value across the value chain Seamless Tox to early phase Mid to late phase supplies Integration supplies One-stop solution from research to Commercial commercial production supplies Medicinal & Synthetic Biology Chemistry Manufacturing Computational Regulatory Excellence

  19. Slide 19: Seamless integration across the NCE development value chain

    Seamless integration across the NCE development value chain with focus on small molecules Discovery Development Manufacturing From target ID & validation to IND Stage Complex chemical synthesis from • 700 KL Capacity through Creative Chemistry, Complex development to commercialization. • 80 Producti

  20. Slide 20: Discovery Services from Target Validation to IND

    Discovery Services spanning the entire journey from Target Validation to IND Integrated services: Synthetic & Medicinal Chemistry, CADD, Biology, DMPK and Toxicology Lead Candidate Target Evaluation In vivo Pharmacology HIT ID Toxicology Formulations 19 All rights reserved © 2026 Sai Life Sciences L

  21. Slide 21: Discovery Services (CRO)

    Discovery Services (CRO) Consistent Revenue Growth (₹ Cr) 775 626 Client Stickiness Automation Modalities Expansion 467 497 >65% Revenues from Focus on automation Expanding capabilities 274 customers in FY23-26 and scale in DMPK and in ADCs, TPDs, who availed more than biology, enabling us to Peptid

  22. Slide 22: Discovery Services: Scaling Innovation, Driving Impact

    Discovery Services: Scaling Innovation, Driving Impact >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Expanded Core Colocalized & Tech-Enabled Specialized Next-Gen Capabilities Global Teams Drug Di

  23. Slide 23: Development Services from H2L to Commercial Supply

    Development Services from H2L to Commercial Supply Underpinned by integrated scientific approaches applied in a phase-appropriate manner • Continuous Verification • Control • Continuous Strategy Improvement • Process Definition Optimization Lifecycle • API Developability & Design Strategy Commercial

  24. Slide 24: CMC Services (CDMO)

    CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization Consistent Revenue Growth (₹ Cr) • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India 1,417 • Flexibility to support both small-scale clinical supplies and large

  25. Slide 25: New Modalities: Fortifying foundation to build scale

    New Modalities: Fortifying foundation to build scale New Modalities Revenue Contribution (%) Antibody-Drug Conjugates Peptides Complement peptide discovery with Enhancing conjugation in 7% process and scale-up facilities for Discovery; upgrading to class 6 clinical supplies; focus on containment for

  26. Slide 26: Our Strengths

    Our Strengths 25 All rights reserved © 2026 Sai Life Sciences Limited 25 All rights reserved © 2026 Sai Life Sciences Limited

  27. Slide 27: IT-Driven Excellence: Digitization & Beyond

    IT-Driven Excellence: Digitization & Beyond Digitization Digitalization Digital Transformation 2017 onwards 2022 onwards 2023 onwards • Converting data, documents and • Use of digitized data for effective • Integration of digital processes from paper/ analog to digital​ monitoring through visual tec

  28. Slide 28: Global-Standard Operations, End-to-End

    Global-Standard Operations, End-to-End Quality Assurance Sustainability Leadership Safety & EHS Leadership • 350+ QA/QC professionals across • 100% renewable energy at Bidar site • Embedded Process Safety from sites quote to execution phase; rigorous • Zero Liquid Discharge: water-neutral lifecycle

  29. Slide 29: Annexure

    Annexure All rights reserved © 2026 Sai Life Sciences Limited 28 28 All rights reserved © 2026 Sai Life Sciences Limited

  30. Slide 30: Consolidated Statement of Profit and Loss

    Consolidated Statement of Profit and Loss Particulars (₹ Cr) Q2FY27 Q1FY27 Q2FY26 H1FY27 H1FY26 Revenue from operations 659 554 537 1213 1034 Other income 3 4 5 7 11 Total income 662 558 542 1220 1045 Expenses Cost of materials consumed and changes in inventories 175 145 140 320 281 Employee benefit

  31. Slide 31: Consolidated Balance Sheet

    Consolidated Balance Sheet Assets (₹ Cr) Sep 26 Mar 26 Equity and Liabilities (₹ Cr) Sep 26 Mar 26 Non current assets Equity Property, plant, and equipment 1,741 1,534 Equity share capital 21 21 Right of use of assets 287 274 Other equity 2,667 2,463 Capital work in progress 560 270 Total equity 2,6

  32. Slide 32: Awards, Certifications & Accreditations

    Awards, Certifications & Accreditations Accelerating the Discovery, Development Member of: and Manufacturing of small molecules ISO 14001:2015, ISO 45001:2018, ISO 50001:2018 & ISO 27001:2022 certifications Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013 Cert

  33. Slide 33: Glossary

    Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste

  34. Slide 34: Thank You

    Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India. 33 All rights reserved © 2026 Sai Life Sciences Limited

Sai Life Sciences — Q2 FY2027 Earnings Presentation on 6ix